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Abstract
Background: Antimicrobial peptides (AMPs) play important roles in the innate immune system of all life forms and
recently have been characterized as multifunctional peptides that have a variety of biological roles such as anticancer
agents. However, detailed mechanism of antimicrobial peptides on cancer cells is still largely unknown.
Methods: miRNA array and real-time qPCR were performed to reveal the behavior of miRNA in colon cancer HCT116
cells during the growth suppression induced by the AMPs. Establishment of miR-663a over-expressing HCT116 cells
was carried out for the evaluation of growth both in vitro and in vivo. To identify the molecular mechanisms, we used
western blotting analysis.
Results: miR-663a is upregulated by administration of the human cathelicidin AMP, LL-37, and its analogue peptide,
FF/CAP18, in the colon cancer cell line HCT116. Over-expression of miR-663a caused anti-proliferative effects both in
vitro and in vivo. We also provide evidence supporting the view that these effects are attributed to suppression of the
expression of the chemokine receptor CXCR4, resulting in the abrogation of phosphorylation of Akt and cell cycle
arrest in G2/M via p21 activation.
Conclusions: This study contributes to the understanding of the AMPs’ mediated anti-cancer mechanisms in colon
cancer cells and highlights the possibility of using AMPs and miRNAs towards developing future strategies for cancer
therapy.
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Background
Colon cancer represents the third most commonly diag-
nosed malignancy in males and the second in females
with more than 1.3 million cases reported and 693,900
deaths recorded in 2012 worldwide [1]. According to
American Cancer Society, in the U.S., estimated new
cases of colon cancer go up to 134,490, and 49,190
people will die in 2016 [2]. Today, six types of standard
treatments are used to fight colon cancer: surgery, radio-
frequency ablation, cryosurgery, chemotherapy, radiation
therapy, and targeted therapy [3]. Chemotherapy is used
before surgery to shrink the tumor, after surgery, or both
before and after for patients with advanced stage cancer.
A huge range of mutations such as chromosomal trans-
locations, amplifications, and deletions can induce can-
cer development. If tumors are diagnosed with identical
histopathology, mutations in each cancer can be differ-
ent [4, 5]. Therefore, all therapeutic strategies, including
chemotherapy, designed to target individual signaling
molecules have limitations in improving current survival
rates. Thus, the effectiveness of chemotherapeutic agents
is not uniform among patients, and the discovery of bio-
logical factors and novel therapeutic strategies is very
important for colon cancer treatment.
microRNAs (miRNAs) are small, endogenous, single-
stranded RNAs of 18–22 nucleotides in length, that are
emerging as important modulators of gene expression.
miRNAs participate in diverse biological processes such
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as cell differentiation, proliferation, and apoptosis
through a myriad of targets [6]. Recent studies have pro-
vided several insights into the relationship between miR-
NAs and colon cancer, and miRNAs are potentially
crucial for successful colon cancer therapy [7, 8].
Antimicrobial peptides (AMPs) play important roles in
the innate immune system of all forms of life [9]. Ac-
cording to the AMP database (http://aps.unmc.edu/AP/
main.php), over 2700 such peptides have been reported
with more than 190 peptides listed as anti-cancer
peptides. We previously reported that FF/CAP18, the
analogue peptide of human cathelicidin AMP, can in-
duce apoptotic cell death on SAS-H1 squamous cells
carcinoma-derived cell line [10] and HCT116 cells colon
cancer-derived cell line [11]. Although the relationships
between several cancers and AMPs have been widely
evaluated, there are many limitations in applying AMPs
as new strategies for cancer therapy, such as digestive
system complications and production costs. Therefore,
investigating the mechanisms of AMPs effects against
colon cancer from a wider perspective is needed to ob-
tain novel therapeutic targets and strategies.
These observations triggered our interest to investigate
the regulation and effects of miRNAs expression by
AMPs in colon cancer cells. Here, we report that miR-
663a is upregulated by the administration of human
cathelicidin LL-37 and its analogue peptide FF/CAP18
in the colon cancer cell line HCT116. Our findings sug-
gest that miR-663a modulates HCT116 cells by modulat-
ing cell proliferation and apoptosis, suppressing the
chemokine receptor CXCR4, abrogating phosphorylation
of Akt, and arresting the cell cycle at the G2/M phase
via activation of p21. These results suggest that the in-
duction of miR-663a and the consequent modulation of
the CXCR4-p21 pathway could be targeted by AMPs for
cancer treatment.
Methods
Cell line and reagents
Dr. Bert Vogelstein (Johns Hopkins University, Baltimore,
MD, USA) provided the human HCT116 colon carcinoma-
derived cell line. The cells were maintained in Dulbecco’s
modified Eagle medium (Nacalai Tesque, Kyoto, Japan)
containing 10% fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) and a 5% antibiotic/antimycotic mixed stock so-
lution (Nacalai Tesque) at 37 °C and 5% CO2. Before being
used for the experiments, cells were routinely maintained
under exponential-proliferation conditions. The cells were
treated with a 0.25% trypsin-EDTA solution (Nacalai
Tesque) to dislodge them at each passage.
The primary structure of LL-37 in single amino acid
code is as follows: LLGDFFRKSKEKIGKEFKRIVQ-
RIKDFLRNLVPRTES. To enhance the antimicrobial ac-
tivity, FF/CAP18 was designed by the replacement of a
glutamic acid residue and a lysine residue with phenyl-
alanine at positions 11 and 20, respectively, of the 27mer
(FRKSKEKIGKEFKRIVQRIKDFLRNLV), which resulted
from the removal of the first and last five amino acids of
LL-37 [12]. FF/CAP18 (FRKSKEKIGKFFKRIVQRIFDF
LRNLV) and its scrambled control peptide (Sc/FF:
IKLIRFRGDVKQRFIKLERSFNKFFKV) were synthesized
by the method previously described [10].
miRNA micro array
HCT116 cells were seeded at a density of 5.0 × 105 cells/
well in a 6-well plate. After 24 h of incubation, cells were
treated with LL-37 (40 μg/mL and 80 μg/mL) and FF/
CAP18 (10 μg/mL and 40 μg/mL) for 24 h. Total RNA,
including miRNA, was extracted using the miRNeasy
Mini Kit (QIAGEN, Venlo, The Netherlands) according
to the manufacturer’s instructions. RNAs quality (con-
centrations, OD260/280 and OD260/230) were mea-
sured using a BioSpec-nano (Shimadzu, Kyoto, Japan),
and 100 ng of each total RNA was analyzed. Labeling
and hybridization were conducted using the miRNA
Complete Labeling Reagent and Hyb kit (Agilent
Technologies, Santa Clara, CA), and then scanned on an
Agilent Technologies Microarray Scanner (Agilent
Technologies). Each spot was quantified using Agilent
Feature Extraction 10.7.3.1 (Agilent Technologies).
RT-qPCR
To conduct the quantitative reverse transcription PCR
(RT-qPCR) for the detection of miR-663a expression
level, complementary DNA (cDNA) synthesis from
miRNA was performed using miRCURY LNA™ Universal
RT microRNA PCR Starter Kit (EXIQON, Vedbaek,
Denmark), according to manufacturer’s instructions.
Then, real-time PCR amplification was performed in a
10 μL solution containing PCR master mix, PCR primer
mix (EXIQON, product no: 204284), and cDNA tem-
plate. Similarly, cDNA synthesis from total RNA was
carried out using PrimeScript™ II 1st strand cDNA Syn-
thesis Kit (TaKaRa Bio, Shiga, Japan) and RT-PCR was
performed in a 12.5 μL solution containing 2 × SYBR
Premix Ex Taq II (Tli RNaseH Plus, TaKaRa Bio), 1 μL
cDNA, and 0.4 μM of each primer. The sequences of the
primers are available in Additional file 1: Table S1). Each
RT-qPCR assay was performed in triplicate using the
Thermal Cycler Dice Real Time System Single (TaKaRa
Bio). Relative expression levels were calculated by the
ΔΔCt method. The expression levels of target genes such
as miR-663a and other genes were normalized to U6
and GAPDH, respectively.
Establishment of miRNA over-expressing cells
To establish miR-663a over-expressing colon cancer
cells, pLV-[hsa-mir-663a] plasmid (BioSettia, San Diego,
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CA) was introduced into the HCT116 cells. Recombin-
ant lentiviruses with vesicular stomatitis virus G glyco-
protein were produced as described previously [13].
HCT116 cells were seeded at a density of 1.0 × 105 cells/
well in a 6-well plate and inoculated with pLV-[hsa-mir-
663a] lentivirus at a multiplicity of infection (MOI) of
five for virus in the presence of 6 μg/mL polybrene.
HCT116 cells with pLV-[hsa-mir-ctrl] (empty vector)
were established as a control cell line in a similar man-
ner (HCT116 miR-ctrl). Cells transduced with these
vectors were cloned using 1 μg/mL puromycin adminis-
tered for 48 h before each experiment.
Proliferation assay
Cell proliferation was measured by WST-8 colorimetric
assay (Dojindo, Tokyo, Japan). Cells were seeded in 96-
well plates at a cell density of 2 × 103 and incubated for
24 h. Cells were incubated with or without peptides for
another 48 h at the final concentrations in the range of
1.56–100 μg/mL and the assay was conducted according
to manufacturer’s instructions. WST-8 reagent was
added to each well, and the samples were incubated for
4 h. The absorbance was measured at a wavelength of
450 nm using Synergy™ HT (BioTek, Winooski, VT,
USA). All assays were performed in three independent
experiments (n = 3). Cell viabilities (%) were calculated
as relative values based on the absorbance of non-
treated cells (100%).
Cell cycle analysis
Cell cycle analysis was carried out using the Muse Cell
Cycle Kit and Muse Cell Analyzer (Merck Millipore,
Darmstadt, Germany). Cells were harvested by trypsini-
zation and fixed by 70% ice-cold ethanol. After fixation,
cell pellets were resuspended in Muse Cell Cycle Kit re-
agent, incubated for 30 min, and protected from light
until further analysis. Cell cycle analysis carried out by
the method supplied by the manufacturer.
Western blot analysis
Cells were homogenized in lysis buffer (1 M Tris-HCl at
pH 7.4, 3 M NaCl, 1% Triton X-100, 6 mM sodium deoxy-
cholate, and 0.5% protease inhibitor cocktail (Nacalai
Tesque, Kyoto, Japan). The detailed method for western
blotting has been described in our previous report [14]. A
mouse monoclonal antibody against p21 (1:1000, Medical
& Biological Laboratories Co., LTD., Aichi, Japan), p53
(1:1000, Abcam, Cambridge, UK), cdc2 (1:1000, Cell
Signaling Technology (CST), Danvers, MA, USA), and α-
tubulin (1:1000, Santa Cruz Biotechnology, Inc., Dallas,
US), and rabbit monoclonal antibodies against Akt
(1:1000, CST), phospho-Akt (1:2000, CST), and phospho-
cdc2 (1:1000, CST) were used as primary antibodies. The
corresponding secondary antibodies: sheep anti-mouse
IgG conjugated to horseradish peroxidase and sheep anti-
rabbit IgG conjugated to horseradish peroxidase, 1:2000
(GE Healthcare, Little Chalfont, Buckinghamshire, UK)
were used as secondary antibodies. Signals on the mem-
branes were detected using an ECL prime kit (GE Health-
care), and the image was obtained with the LumiCube
(Liponics, Inc., Tokyo, Japan). Signal intensity was quanti-
fied by using the JustTLC software (Sweday, Sodra
Sandby, Sweden).
Xenograft model
Animal experiments were conducted in accordance with
the guideline for the Regulations for Animal Experiments
and Related Activities at Tohoku University (Approval
number: 2016AgA-039). The backs of 6-week- old female
BALB/cA.Jcl-nu/nu (CLEA Japan Inc., Tokyo, Japan) were
inoculated with 5.0 × 106 HCT116 cells. Tumor size was
monitored at 2-day intervals by measuring the length and
width with calipers, and its volumes were calculated with
the formula: (L ×W2) × 0.5, where L is length and W is
width of each tumor. FF/CAP18 and Sc/FF were co-
administered at 10 mg/kg per mouse. Tumor weight was
determined at day 14. Medetomidine hydrochloride
(0.3 mg/kg), midazolam (4 mg/kg), and butorphanol tar-
trate (5 mg/mL) were administrated by intraperitoneal in-
jection for anesthesia. Mice were sacrificed by cervical
spine fracture dislocation and organs were collected for
pathological examination.
Statistical analysis
The data are expressed as the mean ± SD of three inde-
pendent experiments performed in triplicate. The statis-
tical analyses were performed using the Student’s t test.
A p-value < 0.05 was considered statistically significant.
Results
miR-663a is a major upregulated miRNA in HCT116 cells
treated with LL-37 and FF/CAP18
The cathelicidin antimicrobial peptide, LL-37, induced
growth suppression significantly in the colon cancer cell
line HCT116 (Fig. 1a) at a concentration higher than
50 μg/mL. FF/CAP18, an analogue peptide of LL-37,
suppressed growth more intensely compared to LL-37.
We attempted to reveal the behavior of miRNA in
HCT116 cells during the growth suppression induced by
the AMPs. miRNA array analysis revealed that 17 miR-
NAs were increased 2-fold or greater in HCT116 cells
after treatment with LL-37 (40 μg/mL) compared to that
in non-treated cells (Table 1). Among these miRNAs,
miR-663a and miR-513a-5p were upregulated dose-
dependently after the administration of LL-37. Both
miRNAs showed higher expression levels in HCT116
cells treated with FF/CAP18 than those treated with LL-
37. The expression level of miR-663a increased 80 times
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or greater compared with miR-513a-5p. This result con-
firmed reproducibility in other RT-qPCR experiments
(Fig. 1b). These results prompted us to explore the role
of miR-663a in HCT116 cells.
Over-expression of miR-663a delays cell proliferation in
HCT116 cells
To identify the role of miR-663a in HCT116 cells, we
established over-expressing miR-663a HCT116 cells using
a lentivirus vector system. HCT116 cells transduced with
lentiviruses harboring control vector (Fig. 1c: miR-ctrl
cells) and miR-663a-expressing vector (Fig. 1c: miR-663a
cells) expressed red fluorescence (Fig. 1c: rPuro). The RT-
qPCR identified that HCT116 cells transduced with miR-
663a-expressing vector expressed miR-663a 2–3-folds
higher than control vector-introduced HCT116 cells
(Fig.1d). In miR-663a overexpressing cells, colony morph-
ology was smaller than non-infected cells (wt) and control
cells (Fig. 1c). Moreover, miR-663a over expressing cells
exhibited senescence-like morphology displayed as en-
larged cytosol (Fig. 1c). These morphological features mo-
tivated us to examine the proliferation, and the WST-8
assay revealed that miR-663a expressing cells had sup-
pressed growth compared to HCT116 cells and miR-ctrl
cells (Fig. 1e). Thus, these results suggest that miR-663a is
the main upregulated miRNA stimulated by the anti-
microbial peptides LL-37 and FF/CAP18 and its expres-
sion has an anti-proliferative effect on colon cancer cells.
Anti-proliferative effect of miR-663a is through
p53-independent p21 phosphorylation
We sought to reveal the mechanisms of the anti-
proliferative effect on HCT116 cells due to the upregula-
tion of miR-663a. Cell cycle analysis uncovered that
miR-663a over-expressing cells are arrested in the G2/M
phase compared with wt and miR-ctrl cells, whereas
Fig. 1 miR-663a is the major upregulated miRNA in HCT116 cells treated with LL-37 and FF/CAP18. a Viability of HCT116 cells after treatment with
LL-37, FF/CAP18, or Sc/FF for 48 h at the concentration of 1.56–100 μg/mL. Each data is presented as mean ± SD of triplicate experiments. (* p < 0.05;
** p < 0.001). b Relative expression of miR-663a in HCT116 cells treated with LL-37 (40, 80 μg/mL) and FF/CAP18 (40 μg/mL). Each data is shown
as mean ± SD of triplicate experiments. (* p < 0.05; ** p < 0.001). c Morphology of established over-expressing miR-663a HCT116 cells using the
lentivirus vector system. HCT116 cells transduced with lentiviruses harboring control vector (miR-ctrl) and miR-663a-expressing vector (miR-663a)
expressed red fluorescence (rPuro). d The RT-qPCR analysis showed that HCT116 cells transduced with miR-663a-expressing vector expressed
miR-663a. Each data is shown as mean ± SD of triplicate experiments. (* p < 0.05). e Proliferation of HCT116 cells (wt) and HCT116 cells
transduced with lentiviruses harboring control vector (miR-ctrl) and miR-663a-expressing vector (miR-663a) for 4 days. Each data is presented
as mean ± SD of triplicate experiments. (** p < 0.001)
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cells in G1/G0 phase are decreased (Fig. 2a). Cell cycle is
regulated in a rigorous manner by various regulators.
The p53 gene, called ‘the guardian of the genome,’ is one
of the most important genes for control of the cell cycle
and cell death [15]. This gene expression level was not
changed between the three types of HCT116 cells
(Fig. 2b, upper). Interestingly, p21, the downstream tran-
scription target gene of p53, was upregulated in over-
expressing miR-663a HCT116 cells (Fig. 2b, lower).
These tendencies were also confirmed at protein levels
(Fig. 2c). Moreover, we confirmed expression levels of
the cell cycle regulators involved in the G2/M phase,
total cdc2 protein, and cdc2 phosphorylated at tyrosine
(Tyr) 15. Western blotting revealed that the total cdc2
level in HCT116 miR-663a was lower than that in wt
and miR-ctrl, and the ratio of phospho-cdc2 (Tyr 15)
/total cdc2 (p-cdc2/cdc2) was higher than that in other
two types of HCT116 cells (Fig. 2c). These observations
indicate that miR-663a could cause cell cycle arrest in
the G2/M phase in colon cancer cells mostly through a
p21 dependent mechanism.
Over-expressing miR-663a suppresses tumorigenesis in a
mouse xenograft model
To evaluate the possible anti-tumorigenic effects of miR-
663a, we performed a xenograft model assay. Average
tumor volume between the group inoculated with
HCT116 miR-ctrl and HCT116 miR-663a was significantly
different between 10 and 14 days (Fig. 3a). The tumor
weight of the miR-663a group at 14 days was also lighter
than that of the miR-ctrl group (Fig. 3b). We examined
whether FF/CAP18 has anti-tumorigenesis effects in
HCT116 cells. Tumor volume and final weight were re-
duced significantly in the group of mice simultaneously in-
oculated with HCT116 cells and FF/CAP18 (10 mg/kg)
compared with the Sc/FF (10 mg/kg) inoculation group
(Additional file 2: Figure S1). Histopathologically, subcuta-
neous tumor cells were similar to each other in the xeno-
graft model. There was no translocation to various organs
such as the kidney, spleen, heart, or liver, with only one ex-
ception of the lung in the ctrl group (data not shown).
These results indicate that introduction of miR-663a
suppresses the growth of human colon cancer cells in tu-
mors in vivo and in vitro. Additionally, miR-663a can con-
tribute in inhibiting tumorigenesis of HCT116 cells treated
with FF/CAP18.
Anti-proliferative effects arising from miR-663a are
executed through the CXCR4-Akt pathway
Results so far demonstrate that miR-663a could induce
anti-proliferative effects on colon cancer cells via p21-
associated cell cycle arrest in the p53 independent path-
way. To identify the detailed mechanism of this pathway,
we focused on Akt and CXCR4. Western blotting de-
tected that phospho-Akt and CXCR4 expressions were
decreased in HCT116 miR-663a compared to HCT116
wt and miR-ctrl cells (Fig. 4a).
Discussion
miRNAs play a key role in many crucial biological pro-
cesses such as cell proliferation, differentiation, and
apoptosis in colon cancer, and continued efforts will help
identify new targets for the diagnosis, prognosis, and
management of colon cancer [8, 16, 17]. Recently, miR-
663a, which belongs to the primate specific miRNAs,
was detected as a tumor suppressing miRNA in several
cancer cells including colon cancer cells [18–20]. In the
present study, we identified miR-663a as the upregulated
miRNA in the colon cancer cell line HCT116 treated
with human cathelicidin AMP, LL-37 and its analogue,
FF/CAP18. Moreover, we revealed that upregulated miR-
663a in HCT116 cells induced the suppression of growth
through cell cycle arrest at the G2/M phase.
LL-37 is the C-terminal domain of hCAP18 protein
and known as the only member of the cathelicidin family
AMPs in human. LL-37 is cleaved by the protease from
hCAP18 and shows various effects other than antibacter-
ial activity including immune regulation [21, 22]. LL-37
is expressed in the epithelial cells of numerous organs
[23], and is increasingly recognized as a novel modulator
of tumor growth and metastasis in carcinogenesis of
various cancers [24]. Ren et al. has revealed that LL-37
Table 1 Upregulated miRNAs in HCT116 treated with AMPs
Fold Change
LL-37 FF/CAP18
miRNA 40 mg/mL 80 mg/mL 40 mg/mL
hsa-miR-3663-3p 162.04 ND 58.19
hsa-miR-4271 145.10 ND 359.22
hsa-miR-630 139.54 ND 194.83
hsa-miR-371a-5p 123.04 ND ND
hsa-miR-1181 112.97 ND ND
hsa-miR-575 112.85 ND 315.56
hsa-miR-939-5p 96.13 ND 83.80
hsv2-miR-H6-5p 94.15 ND ND
hsa-miR-663a 61.85 215.81 277.49
hsa-miR-135a-3p 27.81 ND ND
hsa-miR-132-3p 3.21 ND ND
kshv-miR-K12-3-5p 3.16 3.09 ND
hsa-miR-10a-5p 3.05 ND ND
hsa-miR-762 3.03 2.16 ND
hsa-miR-513a-5p 2.26 4.59 8.37
hsa-miR-99a-5p 2.10 ND ND
hsa-miR-1915-3p 2.09 2.41 ND
ND Not detectable
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expression was significantly suppressed in human colon
cancer tissue compared with normal tissue, and LL-37 can
induce caspase-independent apoptosis in colon cancer
cells. Furthermore, in this report, CRAMP, a mouse cathe-
licidin AMP, deficient mice demonstrate high ratio of
carcinogenesis induced by azoxymethane administrations
[25]. However, it has been reported that LL-37 is
expressed in human lung cancer cells (20–30 ng/mL)
and acts as a growth factor [26]. In this report, how-
ever, the concentration of LL-37 necessary to activate
lung cancer cell proliferation was in the order of ng/
mL, whereas the administration of 20 μg/mL LL-37 de-
creased the cell numbers. In prostate cancer and ovar-
ian cancer, LL-37 is also overexpressed and associated
with proliferation [27, 28]. These observations suggest
that the role of LL-37 in each cancer is different and its
control is surprisingly complicated, which results in
one of the limitations of its application in cancer
treatment. The relationship between AMPs and cancer
is not discussed with regard to miRNAs to date, thus
this study is the first report. As previously described,
miR-663a has been reported to be associated with can-
cer suppression in several cancers, although its in-
creased level was found in lung cancer, ovarian cancer
[29, 30], and castration-resistant prostate cancer [31].
These observations indicate that the differential sensi-
tivity of LL-37 among cancer types is associated with
the expression of miR-663a, although further investiga-
tion is needed.
C-X-C chemokine receptor type 4 (CXCR4) is broadly
expressed in various malignant tumors including colon
cancer [32]. CXCR4 is upregulated by the microenviron-
ment, and isolated metastatic cells likely require CXCR4
signals to initiate their proliferation, suggesting that
CXCR4 inhibitors have potential as anticancer agents to
suppress the outgrowth of micrometastasis [33]. The
Fig. 2 miR-663a induced cell cycle arrest following p21 expression and accumulation of the inactive form of cdc2 in HCT116 cells. a Cell cycle
was examined by the MUSE cell analyzer and representative data are shown. The percentage of cells in G0/G1, S, and G2/M phases are presented
as mean ± SD of triplicate experiments. (** p < 0.001). b The mRNA expression of p21 and p53 were determined by qPCR and relative expression
levels are shown as mean ± SD of triplicate experiments. (** p < 0.001). c Protein levels of p53, p21, cdc2, phospho-cdc2 (Tyr15), and αtubulin in
the total cell lysates were determined by western blotting analysis. Representative data of three experiments are shown. Ratio of phospho-cdc2
(Tyr15)/cdc2 was calculated after digitalization by using JustTLC and shown as mean ± SD of triplicate experiments. (** p < 0.001)
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Fig. 3 miR-663a suppresses tumorigenesis of HCT116 in a xenograft model. a Growth curves of HCT116 tumors after nude mice were injected
with miR-663a (square) or control miRNA (triangle). The volume of the tumors derived from both cells was evaluated at 2-day intervals for 14 days
and plotted as the percentage relative to day 0. Each plot is shown as mean ± SD of four experiments (* p < 0.05; ** p < 0.001). b Tumor weight
was measured 14 days after the inoculation of over-expressing miR-663a HCT116 cells harboring control vector. Each plot is shown as mean ± SD
of four experiments (** p < 0.001). c Photographs illustrating mice tumors derived from control cells (miR-ctrl: arrows) and over-expressing
miR-663a HCT116 cells (miR-663a) 14 days after inoculation
Fig. 4 miR-663a can target the CXCR4-Akt pathway. a Protein levels of CXCR4, Akt, phospho-Akt, and αtubulin in the total cell lysates were
determined by western blotting analysis. Representative data is shown in triplicate experiments. Ratio of phospho-Akt/Akt was calculated after
digitalization by using JustTLC and shown as mean ± SD of triplicate experiments (** p < 0.001). b Putative model of anti-cancer effect of AMPs in
HCT116 cells. miR-663a upregulated by AMPs suppresses CXCR4 expression leading to reduced phosphorylation of Akt. Consequently, p21 and
the inactive form of cdc2 accumulation are caused, which results in the cell cycle arrest at the G2/M phase
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present study shows that CXCR4 expression was re-
duced in over-expressing miR-663a HCT116 cells, which
resulted in the suppression of proliferation. Yu et al. re-
ports that miR-663a negatively regulates CXCR4 expres-
sion by targeting its coding sequence in human
glioblastoma cells and compromises proliferation [34].
This report suggests that miR-663a directly binds to the
coding sequence of CXCR4 mRNA to suppress its transla-
tion. Thus, the suppression of proliferation in over-
expressing miR-663a colon cancer cells might be induced
by the same mechanism as in glioblastoma cells. We con-
firm down-regulation of CXCR4 protein expression and
upregulation of the p-cdc2/cdc2 ratio in HCT116 cells
treated with FF/CAP18 (Additional file 3: Figure S2),
which demonstrates that one of the pathways of the anti-
cancer mechanism of AMPs can be triggered by targeting
CXCR4 via miR-663a overexpression and changing the
downstream signals containing p21 and cdc2 (Fig. 4b).
From previous reports, the mechanism of the anti-
cancer effects of AMPs against cancer cells includes mul-
tiple directions such as apoptosis, necrosis, and autophagy
[35–37]. We previously reported that FF/CAP18 induces
apoptotic cell death in HCT116 cells through dynamic
changes in the levels of metabolic profiles and revealed
that the glycolytic pathway was restricted, resulting in re-
duced energy status [38]. To reveal the relationship be-
tween miR-663a and metabolism in HCT116 cells, we
have performed metabolome analysis in a similar way. We
could not observe appreciable changes in the glycolytic
pathway and energy status (Additional file 4: Figure S3).
Furthermore, we confirmed that LL-37 and FF/CAP18 in-
duce anti-proliferative effect on another colon cancer cell
line, Caco2, which was accompanied by the upregula-
tion of miR-663a expression as well as on HCT116 cells
(Additional file 5: Figure S4). These data support previ-
ous hypotheses that AMPs can act against cancer, in-
cluding colon cancer, through a variety of mechanisms
of action, and the modulation of miR-663a could be
just one factor inducing the negative effect on cancer
by the administration of AMPs.
We showed that miR-663a inhibits the growth of
colon cancer cells in vitro and in vivo by upregulating
p21 gene expression and the subsequent induction of
cell cycle arrest and apoptosis. Similar result has been
reported about miR-6734 in the colon cancer cell
HCT116 [39]. In this study, miRNA microarray identi-
fied 17 miRNAs, including miR-663a, as upregulated
miRNAs in HCT116. However, miR-6734 was not up-
regulated. Thus, the regulation system of cancer growth
can include various signal controls via miRNA.
Recently, new drug delivery systems have been studied
to improve AMP’s activities and overcome transporta-
tion problems. For instance, theranostics and drug deliv-
ery strategies using magnetic anti-cancer drugs are
expected to bring new hope for cancer therapy [40]. In-
deed, Niemirowicz et al. reported that magnetic nano-
particles enhance the anticancer activity of LL-37 against
colon cancer cells [41]. Moreover, using mesoporous sil-
ica nanoparticles has been investigated [42]. Therefore,
AMPs, including LL-37 and its modified peptides, have
the potential to be anticancer agents if they are appro-
priately targeted using these drug delivery systems.
Conclusions
We report that human cathelicidin antimicrobial peptide,
LL-37, and its analogues suppress the proliferation of
colon cancer cells via the upregulation of miR-663a abro-
gating CXCR4 expression. This study contributes to the
understanding of anti-cancer mechanisms in colon cancer
cells treated with AMPs, and highlights the possibility of
using AMPs for future strategies in cancer therapy.
Additional files
Additional file 1: Table S1. List of primers. (DOCX 40 kb)
Additional file 2: Figure S1. FF/CAP18 suppresses tumorigenesis of
HCT116 in a xenograft model. (A) Growth curves of HCT116 tumors after
simultaneous injection of nude mice with FF/CAP18 (square) or control
peptide, Sc/FF (triangle). The volume of the tumors was derived from
both cells evaluated at 2-day intervals for 14 days and plotted as the
percentage relative to day 0. Each plot is shown as mean ± SD of four
experiments (* p < 0.05; ** p < 0.001). (B) Tumor weight was measured
14 days after inoculation of HCT116 cells with Sc/FF and FF/CAP18. Each plot
is shown as mean ± SD of four experiments (* p < 0.05). (C) Photographs
illustrating mice tumors derived from control cells treated with Sc/FF (Sc/FF:
arrows) and HCT116 cells treated with FF/CAP18 (FF/CAP18) 14 days after
inoculation. (JPG 379 kb)
Additional file 3: Figure S2. Suppression of CXCR4 and
phosphorylation of cdc2 are observed in HCT116 cells treated with FF/
CAP18. (A) Protein levels of CXCR4, cdc2, phospho-cdc2, and α-tubulin in
the total cell lysate were determined by western blotting analysis.
Representative data are shown in triplicate experiments. Ratio of
phospho-cdc2/cdc2 was calculated after digitalization by using
JustTLC and shown as mean ± SD of triplicate experiments. (** p < 0.001).
(JPG 296 kb)
Additional file 4: Figure S3. Metabolome data map of the glycolysis
metabolic pathway in HCT116 cells. Each bar represents the relative
amount of a metabolite for HCT116 (blue) transduced with control vector
(red) or miR-663a over-expressing vector (green). All metabolite data are
shown as the mean of triplicate samples ± SD. Detailed materials and
methods are shown in our previous manuscript [38]. (JPG 522 kb)
Additional file 5: Figure S4. miR-663a is upregulated in Caco2 cells
treated with LL-37 and FF/CAP18 the same as in HCT116 cells. (A) Viability
of Caco2 cells after treatment with LL-37, FF/CAP18, or Sc/FF for 48 h at
the concentration of 100–1.5625 μg/mL. Each data is presented as mean ± SD
of triplicate experiments. (* p< 0.05; ** p< 0.001). Caco2 cells were purchased
from RIKEN Bioresource Center (RBRC-RCB0988) and maintained in a same
condition as HCT116 cells. (B) Relative expression of miR-663a in Caco2 cells
treated with LL-37 (40, 80 μg/mL) and FF/CAP18 (40 μg/mL). Each data is
shown as mean ± SD of triplicate experiments. (* p < 0.05; ** p < 0.001).
(JPG 469 kb)
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